Nrf2 also seems to be able to modulate cellular function in RA because the administration of S-propargyl-cysteine, which is a potent activator of the Nrf2 pathway, leads to alleviation of RA symptoms in a rat model and reduces the production of inflammatory cytokines in human rheumatoid fibroblast-like synoviocytes [61]. Here, NFE2L2 is linked to rheumatoid arthritis.